BofA raised the firm’s price target on Tandem Diabetes (TNDM) to $35 from $30 and keeps a Neutral rating on the shares. The firm, which rebuilt its revenue model to now reflect the pay-as-you-go and pharmacy channel dynamics, thinks there’s still some risk with the transition, but feels “better about the 2027+ upside opportunity,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Closing Bell Movers: Keysight rallies 15% after earnings beat
- Tandem Diabetes announces proposed private placement of $200M convertible notes
- Alphabet, Nvidia upgraded: Wall Street’s top analyst calls
- Tandem Diabetes upgraded to Buy from Hold at Lake Street
- Tandem Diabetes price target raised to $27 from $24 at Truist